Of the other genes that we identified in the 1st priority group, CHST9 is a sulfo-transferase and the CHST9 gene was recently shown to be amplified in multiple types of hematological malignancies 18.
Of all hematological malignancies, multiple myeloma was associated with the highest risk (HR = 3.4; 2.3–5.0, P < 0.0001).
In hematological malignancies, multiple studies have established comorbid disease overall as an independent predictor of all-cause mortality [ 9– 14], especially among patients eligible for hematopoietic stem cell transplantation [ 15– 17].
By coupling immunomagnetic and fluorescence-based cell separation with microarray gene expression profiling, researchers have dramatically improved the understanding of how hematological malignancies, including Multiple Myeloma (MM), develop, progress, and respond to therapy.
Immunomodulatory drugs (IMiD) are a novel class of orally available antineoplastic agents that have made an important impact on the treatment of patients with hematological malignancies, particularly multiple myeloma (MM).
Agents with both anti-tumor and bone-anabolic actions have been tested in the setting of multiple myeloma, a hematological malignancy that causes severe osteolytic bone loss and suppression of osteoblastic new bone formation.
The proteasome inhibitors bortezomib and carfilzomib produce clinical responses in hematological malignancies, such as multiple myeloma and mantle cell lymphoma.
These include cancers, 14, 15 hematological malignancies, 16, 17 multiple sclerosis, 18 CD, UC, 19, 20– 22 and other diseases.
Examples of those at risk include persons with a primary or hereditary immunodeficiency, persons on antineoplastic therapy, immunosuppressive drugs, glucocorticoids, those with hematological malignancies (leukemia, lymphoma, multiple myeloma), and of course HIV infection.
Multiple Myeloma is one of the hematological malignancies that is caused by an unregulated proliferation of a single clone of plasma cells in the bone marrow leading to anemia, thrombocytopenia, bone destruction and pathological fractures.
